Table 2 Cell migration expressed with time to heal 50% of the wound (T50) and p-values.
From: Dual “mAb” HER family blockade in head and neck cancer human cell lines combined with photon therapy
T50 (h) [CI95%] | p-value (Vs Control) | p-value (Vs 10 Gy) | p-value (Vs Cetuximab) | |
|---|---|---|---|---|
SQ20B | ||||
Control | 15.5 [12.9–18.1] | — | — | — |
Pertuzumab | 15.4 [12.8–17.9] | 0.94 | — | — |
Cetuximab | 37.8 [31.5–44.1] | <0.001 | — | — |
Cetuximab + Pertuzumab | 52.6 [43.4–61.8] | <0.001 | — | 0.0086 |
10 Gy | 19.7 [15.8–23.6] | — | — | — |
10 Gy + Pertuzumab | 17 [13.7–20.3] | — | 0.3 | — |
10 Gy + Cetuximab | 43.6 [34.9–52.2] | — | <0.001 | — |
10 Gy + Cetuximab + Pertuzumab | 69.3 [54.4–84.2] | — | <0.001 | 0.0013 |
SQ20B-CSCs | ||||
Control | 20 [13.3–26.6] | — | — | — |
Pertuzumab | 23.7 [15.6–31.7] | 0.49 | — | — |
Cetuximab | 19.2 [12.7–25.7] | 0.86 | — | — |
Cetuximab + Pertuzumab | 54.8 [36.2–73.4] | <0.001 | — | <0.001 |
10 Gy | 20.9 [13.8–27.9] | — | — | — |
10 Gy + Pertuzumab | 31.4 [20.8–41.9] | — | 0.093 | — |
10 Gy + Cetuximab | 19 [12.5–24.5] | — | 0.7 | — |
10 Gy + Cetuximab + Pertuzumab | 71.1 [45.6–96.6] | — | <0.001 | <0.001 |
FaDu | ||||
Control | 16.3 [11.8–20.8] | — | — | — |
Pertuzumab | 15.8 [11.5–20.1] | 0.89 | — | — |
Cetuximab | 31 [22.6–39.4] | 0.0011 | — | — |
Cetuximab + Pertuzumab | 46 [33.4–58.5] | <0.001 | — | 0.0491 |
10 Gy | 17.1 [12.4–21.8] | — | — | — |
10 Gy + Pertuzumab | 23.2 [16.9–29.5] | — | 0.11 | — |
10 Gy + Cetuximab | 31.6 [22.9–40.2] | — | 0.0017 | — |
10 Gy + Cetuximab + Pertuzumab | 99.6 [70.2–129] | — | <0.001 | <0.001 |
